Co-reporter:Alice Collier, Gerd K. Wagner
Carbohydrate Research 2017 Volume 452(Volume 452) pp:
Publication Date(Web):27 November 2017
DOI:10.1016/j.carres.2017.09.010
•GDP-mannose derivatives with an additional substituent at the base are donor substrates for the S. cerevisiae α-1,2-mannosyltransferase Kre2p.•The additional substituent redirects donor substrate activity from glycosyl transfer to donor hydrolysis.•Position and steric bulk of the additional substituent, as well as conformational preferences, are determining factors for the observed activities.We have previously developed a new class of inhibitors and chemical probes for glycosyltransferases through base-modification of the sugar-nucleotide donor. The key feature of these donor analogues is the presence of an additional substituent at the nucleobase. To date, the application of this general concept has been limited to UDP-sugars and UDP-sugar-dependent glycosyltransferases. Herein, we report for the first time the application of our approach to a GDP-mannose-dependent mannosyltransferase. We have prepared four GDP-mannose derivatives with an additional substituent at either position 6 or 8 of the nucleobase. These donor analogues were recognised as donor substrates by the mannosyltransferase Kre2p from yeast, albeit with significantly lower turnover rates than the natural donor GDP-mannose. The presence of the additional substituent also redirected enzyme activity from glycosyl transfer to donor hydrolysis. Taken together, our results suggest that modification of the donor nucleobase is, in principle, a viable strategy for probe and inhibitor development against GDP-mannose-dependent GTs.Download high-res image (155KB)Download full-size image
Co-reporter:Jingqian Jiang, Gerd K. Wagner
Carbohydrate Research 2017 Volume 450(Volume 450) pp:
Publication Date(Web):10 October 2017
DOI:10.1016/j.carres.2017.08.012
•The known β-1,4-galactosyltransferase inhibitor GlcNAc β1-(2-naphthyl) can also behave as an acceptor substrate.•This acceptor substrate activity is promoted by the presence of a phosphatase in the assay mixture.•A kinetic model is proposed that reconciles the substrate and inhibitory activity of GlcNAc β1-(2-naphthyl).Many glycosyltransferase inhibitors in the literature are structurally derived from the donor or acceptor substrate of the respective enzyme. A representative example is 2-naphthyl β-d-GlcNAc, a synthetic GlcNAc glycoside that has been reported as a galactosyltransferase inhibitor. This GlcNAc derivative is attractive as a chemical tool compound for biological and biochemical studies because of its reported potency as an inhibitor, and its short and straightforward synthesis from readily available starting materials. We report that in our hands, 2-naphthyl β-d-GlcNAc behaved, unexpectedly, as an acceptor substrate of the inverting β-1,4-galactosyltransferase (β-1,4-GalT) from bovine milk. This substrate activity has not previously been described. We found that 2-naphthyl β-d-GlcNAc can be an acceptor substrate both for recombinantly expressed β-1,4-GalT, and for a commercial batch of the same enzyme, and both in the presence and absence of bovine serum albumin (BSA). As expected for a full acceptor substrate, this substrate activity was time- and concentration-dependent. Additional experiments show that the observed inhibitor/substrate switch is facilitated by a phosphatase that is an essential component of our enzyme-coupled glycosyltransferase assay. These findings suggest that the behaviour of 2-naphthyl β-d-GlcNAc and related acceptor-based glycosyltransferase inhibitors is strongly dependent on the individual assay conditions. Our results therefore have important implications for the use of 2-naphthyl β-d-GlcNAc and related glycosides as tool compounds in glycobiology and glycobiochemistry.Download high-res image (122KB)Download full-size image
Co-reporter:Yong Xu, Ruth Smith, Mirella Vivoli, Masaki Ema, Niina Goos, Sebastian Gehrke, Nicholas J. Harmer, Gerd K. Wagner
Bioorganic & Medicinal Chemistry 2017 Volume 25, Issue 12(Issue 12) pp:
Publication Date(Web):15 June 2017
DOI:10.1016/j.bmc.2017.04.006
Non-substrate-like inhibitors of glycosyltransferases are sought after as chemical tools and potential lead compounds for medicinal chemistry, chemical biology and drug discovery. Here, we describe the discovery of a novel small molecular inhibitor chemotype for LgtC, a retaining α-1,4-galactosyltransferase involved in bacterial lipooligosaccharide biosynthesis. The new inhibitors, which are structurally unrelated to both the donor and acceptor of LgtC, have low micromolar inhibitory activity, comparable to the best substrate-based inhibitors. We provide experimental evidence that these inhibitors react covalently with LgtC. Results from detailed enzymological experiments with wild-type and mutant LgtC suggest the non-catalytic active site residue Cys246 as a likely target residue for these inhibitors. Analysis of available sequence and structural data reveals that non-catalytic cysteines are a common motif in the active site of many bacterial glycosyltransferases. Our results can therefore serve as a blueprint for the rational design of non-substrate-like, covalent inhibitors against a broad range of other bacterial glycosyltransferases.Download high-res image (175KB)Download full-size image
Co-reporter:Jingqian Jiang, Varsha Kanabar, Beatriz Padilla, Francis Man, Simon C. Pitchford, Clive P. Page and Gerd K. Wagner
Chemical Communications 2016 vol. 52(Issue 20) pp:3955-3958
Publication Date(Web):16 Feb 2016
DOI:10.1039/C5CC09289B
We report 5-substituted uridine derivatives as novel, uncharged inhibitors of β-1,4-galactosyltransferase and chemical tools for cellular applications. The new inhibitors reduce P-selectin glycoprotein 1 (PSGL-1) expression in human monocytes. Our results also provide novel insights into a unique mode of glycosyltransferase inhibition.
Co-reporter:Giulia Pergolizzi, Marco M. D. Cominetti, Julea N. Butt, Robert A. Field, Richard P. Bowater and Gerd K. Wagner
Organic & Biomolecular Chemistry 2015 vol. 13(Issue 22) pp:6380-6398
Publication Date(Web):14 May 2015
DOI:10.1039/C5OB00294J
We report the chemical synthesis and conformational analysis of a collection of 2-, 6- and 8-substituted derivatives of β-NAD+ and AMP, and their biochemical evaluation against NAD+-dependent DNA ligases from Escherichia coli and Mycobacterium tuberculosis. Bacterial DNA ligases are validated anti-microbial targets, and new strategies for their inhibition are therefore of considerable scientific and practical interest. Our study includes several pairs of β-NAD+ and AMP derivatives with the same substitution pattern at the adenine base. This has enabled the first direct comparison of co-substrate and inhibitor behaviour against bacterial DNA ligases. Our results suggest that an additional substituent in position 6 or 8 of the adenine base in β-NAD+ is detrimental for activity as either co-substrate or inhibitor. In contrast, substituents in position 2 are not only tolerated, but appear to give rise to a new mode of inhibition, which targets the conformational changes these DNA ligases undergo during catalysis. Using a molecular modelling approach, we highlight that these findings have important implications for our understanding of ligase mechanism and inhibition, and may provide a promising starting point for the rational design of a new class of inhibitors against NAD+-dependent DNA ligases.
Co-reporter:Ben A. Wagstaff, Martin Rejzek, Thomas Pesnot, Lauren M. Tedaldi, Lorenzo Caputi, Ellis C. O’Neill, Stefano Benini, Gerd K. Wagner, Robert A. Field
Carbohydrate Research 2015 Volume 404() pp:17-25
Publication Date(Web):2 March 2015
DOI:10.1016/j.carres.2014.12.005
•Enzymatic conversion of 5-aryl-substituted UTP to UDP-galactose derivatives.•UDP-glucose pyrophosphorylase was particularly effective.•Epimerization of 5-substituted UDP-glucoses with Erwinia UDP-glucose 4″-epimerase.Glucose-1-phosphate uridylyltransferase in conjunction with UDP-glucose pyrophosphorylase was found to catalyse the conversion of a range of 5-substituted UTP derivatives into the corresponding UDP-galactose derivatives in poor yield. Notably the 5-iodo derivative was not converted to UDP-sugar. In contrast, UDP-glucose pyrophosphorylase in conjunction with inorganic pyrophosphatase was particularly effective at converting 5-substituted UTP derivatives, including the iodo compound, into a range of gluco-configured 5-substituted UDP-sugar derivatives in good yields. Attempts to effect 4″-epimerization of these 5-substituted UDP-glucose with UDP-glucose 4″-epimerase from yeast were unsuccessful, while use of the corresponding enzyme from Erwinia amylovora resulted in efficient epimerization of only 5-iodo-UDP-Glc, but not the corresponding 5-aryl derivatives, to give 5-iodo-UDP-Gal. Given the established potential for Pd-mediated cross-coupling of 5-iodo-UDP-sugars, this provides convenient access to the galacto-configured 5-substituted-UDP-sugars from gluco-configured substrates and 5-iodo-UTP.Figure optionsDownload full-size imageDownload as PowerPoint slide
Co-reporter:Lauren Tedaldi, Andrew Evitt, Niina Göös, Jingqian Jiang and Gerd K. Wagner
MedChemComm 2014 vol. 5(Issue 8) pp:1193-1201
Publication Date(Web):23 May 2014
DOI:10.1039/C4MD00077C
We have developed an operationally simple assay protocol for the identification and evaluation of small molecular glycosyltransferase inhibitors. Wu and co-workers have recently reported that the formation of the nucleoside diphosphate during the glycosyltransferase reaction can be monitored with a phosphatase/malachite green detection system at 620 nm. Here we demonstrate, for the first time, that this assay principle can be exploited for enzyme inhibition studies, and report the optimisation of several key parameters of this assay. We have significantly improved the reproducibility of the assay by addition of chicken egg-white lysozyme as a carrier protein. We have also substantially reduced the assay running costs by using the inexpensive and widely available calf intestinal phosphatase. Critically for inhibition studies with small organic molecules, our assay protocol tolerates additives such as the solubiliser DMSO and the surfactant Triton-X 100, and we have validated its application in inhibition experiments with two known galactosyltransferase ligands. The new assay protocol is robust and inexpensive, requires only short incubation times, and can be carried out in a microplate format. These characteristics make it ideal for high-throughput screening (HTS) campaigns. As it does not require specialist equipment and can readily be performed in non-biochemistry laboratories, we anticipate that the assay will help expedite the identification of new glycosyltransferase inhibitors both in industry and academia.
Co-reporter:Lauren Tedaldi and Gerd K. Wagner
MedChemComm 2014 vol. 5(Issue 8) pp:1106-1125
Publication Date(Web):11 Jul 2014
DOI:10.1039/C4MD00086B
Glycosyltransferases (GTs) are a large family of carbohydrate-active enzymes, which act as nature's glycosylation agents. GTs catalyse the transfer of a mono- or oligosaccharide from a glycosyl donor to an individual acceptor, and play a central role in the biosynthesis of complex carbohydrates, glycans and glycoconjugates. Several GTs have emerged as potential drug targets in a range of therapeutic areas, including infection, inflammation and cancer. Small molecular GT inhibitors are therefore sought after not only as chemical tools for glycobiology, but also as potential lead compounds for drug discovery. Most existing GT inhibitors are donor or acceptor analogues with limited potential for further development due to intrinsic drawbacks, such as a lack of cell penetration and limited chemical stability. In this article, we review recent progress in the identification of alternative inhibitor chemotypes that are not structurally derived from GT donors or acceptors. This growing class of non-substrate-like GT inhibitors now includes several examples with drug-like properties, which provide exciting new starting points for medicinal chemistry and drug discovery. The increasing availability of such alternative GT inhibitor chemotypes represents a significant advance, which will help realise the considerable potential of this important enzyme family as therapeutic targets.
Co-reporter:Thomas Pesnot, Lauren M. Tedaldi, Pablo G. Jambrina, Edina Rosta and Gerd K. Wagner
Organic & Biomolecular Chemistry 2013 vol. 11(Issue 37) pp:6357-6371
Publication Date(Web):14 Aug 2013
DOI:10.1039/C3OB40485D
Derivatives of UMP (uridine monophosphate) with a fluorogenic substituent in position 5 represent a small but unique class of fluorophores, which has found important applications in chemical biology and biomolecular chemistry. In this study, we have synthesised a series of derivatives of the uracil nucleotides UMP, UDP and UTP with different aromatic and heteroaromatic substituents in position 5, in order to systematically investigate the influence of the 5-substituent on fluorescence emission. We have determined relevant photophysical parameters for all derivatives in this series, including quantum yields for the best fluorophores. The strongest fluorescence emission was observed with a 5-formylthien-2-yl substituent in position 5 of the uracil base, while the corresponding 3-formylthien-2-yl-substituted regioisomer was significantly less fluorescent. The 5-(5-formylthien-2-yl) uracil fluorophore was studied further in solvents of different polarity and proticity. In conjunction with results from a conformational analysis based on NMR data and computational experiments, these findings provide insights into the steric and electronic factors that govern fluorescence emission in this class of fluorophores. In particular, they highlight the interplay between fluorescence emission and conformation in this series. Finally, we carried out ligand-binding experiments with the 5-(5-formylthien-2-yl) uracil fluorophore and a UDP-sugar-dependent glycosyltransferase, demonstrating its utility for biological applications. The results from our photophysical and biological studies suggest, for the first time, a structural explanation for the fluorescence quenching effect that is observed upon binding of these fluorophores to a target protein.
Co-reporter:Sebastian S. Gehrke, Erika G. Pinto, Dietmar Steverding, Karin Pleban, Andre G. Tempone, Robert C. Hider, Gerd K. Wagner
Bioorganic & Medicinal Chemistry 2013 Volume 21(Issue 3) pp:805-813
Publication Date(Web):1 February 2013
DOI:10.1016/j.bmc.2012.11.009
Iron is an essential growth component in all living organisms and plays a central role in numerous biochemical processes due to its redox potential and high affinity for oxygen. The use of iron chelators has been suggested as a novel therapeutic approach towards parasitic infections, such as malaria, sleeping sickness and leishmaniasis. Known iron chelating agents such as Deferoxamine and the 3-hydroxypyridin-4-one (HPO) Deferiprone possess anti-parasitic activity but suffer from mammalian toxicity, relatively modest potency, and/or poor oral availability. In this study, we have developed novel derivatives of Deferiprone with increased anti-parasitic activity and reduced cytotoxicity against human cell lines. Of particular interest are several new derivatives in which the HPO scaffold has been conjugated, via a linker, to the 4-aminoquinoline ring system present in the known anti-malaria drug Chloroquine. We report the inhibitory activity of these novel analogues against four parasitic protozoa, Trypanosoma brucei, Trypanosoma cruzi, Leishmania infantum and Plasmodium falciparum, and, for direct comparison, against human cells lines. We also present data, which support the hypothesis that iron starvation is the major cause of growth inhibition of these new Deferiprone–Chloroquine conjugates in T. brucei.Figure optionsDownload full-size imageDownload as PowerPoint slide
Co-reporter:Andrew Evitt, Lauren M. Tedaldi and Gerd K. Wagner
Chemical Communications 2012 vol. 48(Issue 97) pp:11856-11858
Publication Date(Web):05 Nov 2012
DOI:10.1039/C2CC36798J
A one-step synthesis of two 5-CF3 UDP-sugars is reported. These non-natural sugar-nucleotides are micromolar inhibitors of two different galactosyltransferases.
Co-reporter:Karine Descroix ; Thomas Pesnot ; Yayoi Yoshimura ; Sebastian S. Gehrke ; Warren Wakarchuk ; Monica M. Palcic
Journal of Medicinal Chemistry 2012 Volume 55(Issue 5) pp:2015-2024
Publication Date(Web):February 22, 2012
DOI:10.1021/jm201154p
Galactosyltransferases (GalT) are important molecular targets in a range of therapeutic areas, including infection, inflammation, and cancer. GalT inhibitors are therefore sought after as potential lead compounds for drug discovery. We have recently discovered a new class of GalT inhibitors with a novel mode of action. In this publication, we describe a series of analogues which provide insights, for the first time, into SAR for this new mode of GalT inhibition. We also report that a new C-glycoside, designed as a chemically stable analogue of the most potent inhibitor in this series, retains inhibitory activity against a panel of GalTs. Initial results from cellular studies suggest that despite their polarity, these sugar-nucleotides are taken up by HL-60 cells. Results from molecular modeling studies with a representative bacterial GalT provide a rationale for the differences in bioactivity observed in this series. These findings may provide a blueprint for the rational development of new GalT inhibitors with improved potency.
Co-reporter:Lauren M. Tedaldi, Michael Pierce, Gerd K. Wagner
Carbohydrate Research 2012 Volume 364() pp:22-27
Publication Date(Web):15 December 2012
DOI:10.1016/j.carres.2012.10.009
We have investigated the applicability of different chemical methods for pyrophosphate bond formation to the synthesis of 5-substituted UDP-galactose and UDP-N-acetylglucosamine derivatives. The use of phosphoromorpholidate chemistry, in conjunction with N-methyl imidazolium chloride as the promoter, was identified as the most reliable synthetic protocol for the preparation of these non-natural sugar-nucleotides. Under these conditions, the primary synthetic targets 5-iodo UDP-galactose and 5-iodo UDP-N-acetylglucosamine were consistently obtained in isolated yields of 40–43%. Both 5-iodo UDP-sugars were used successfully as substrates in the Suzuki–Miyaura cross-coupling with 5-formylthien-2-ylboronic acid under aqueous conditions. Importantly, 5-iodo UDP-GlcNAc and 5-(5-formylthien-2-yl) UDP-GlcNAc showed moderate inhibitory activity against the GlcNAc transferase GnT-V, providing the first examples for the inhibition of a GlcNAc transferase by a base-modified donor analogue.Graphical abstractHighlights► An optimised chemical synthesis for 5-substituted UDP-sugars was developed. ► NMICl was found to be the optimal promoter for pyrophosphate bond formation. ► Two new derivatives of UDP-GlcNAc were synthesised. ► Both molecules are moderate inhibitors of the GlcNAc transferase GnT-V.
Co-reporter:Giulia Pergolizzi, Julea N. Butt, Richard P. Bowater and Gerd K. Wagner
Chemical Communications 2011 vol. 47(Issue 47) pp:12655-12657
Publication Date(Web):31 Oct 2011
DOI:10.1039/C1CC15499K
A novel, fluorescent NAD derivative is processed as substrate by three different NAD-consuming enzymes. The new probe has been used to monitor enzymatic activity in a continuous format by changes in fluorescence and, in one case, to directly visualize alternative reaction pathways.
Co-reporter:Thomas Pesnot ; Julia Kempter ; Jörg Schemies ; Giulia Pergolizzi ; Urszula Uciechowska ; Tobias Rumpf ; Wolfgang Sippl ; Manfred Jung
Journal of Medicinal Chemistry 2011 Volume 54(Issue 10) pp:3492-3499
Publication Date(Web):April 29, 2011
DOI:10.1021/jm1013852
We report the design and concise synthesis, in two steps from commercially available material, of novel, bioactive derivatives of the enzyme cofactor nicotinamide adenine dinucleotide (NAD). The new synthetic dinucleotides act as sirtuin (SIRT) inhibitors and show isoform selectivity for SIRT2 over SIRT1. An NMR-based conformational analysis suggests that the conformational preferences of individual analogues may contribute to their isoform selectivity.
Co-reporter:Karine Descroix and Gerd K. Wagner
Organic & Biomolecular Chemistry 2011 vol. 9(Issue 6) pp:1855-1863
Publication Date(Web):26 Jan 2011
DOI:10.1039/C0OB00630K
Structural analogues and mimics of the natural sugar-nucleotide UDP-galactose (UDP-Gal) are sought after as chemical tools for glycobiology and drug discovery. We have recently developed a novel class of galactosyltransferase (GalT) inhibitors derived from UDP-Gal, bearing an additional substituent at the 5-position of the uracil base. Herein we report the first C-glycosidic derivative of this new class of GalT inhibitors. We describe a practical convergent synthesis of the new UDP-C-Gal derivative, including a systematic study into the use of radical chemistry for the preparation of galactosyl ethylphosphonate, a key synthetic intermediate. The new inhibitor showed activity against a bacterial UDP-Gal 4′-epimerase at micromolar concentrations. This is the first example of a base-modified UDP-sugar as an inhibitor of a UDP-sugar-dependent enzyme which is not a glycosyltransferase, and these results may therefore have implications for the design of inhibitors of these enzymes in the future.
Co-reporter:Dr. Gerd K. Wagner;Dr. Thomas Pesnot
ChemBioChem 2010 Volume 11( Issue 14) pp:1939-1949
Publication Date(Web):
DOI:10.1002/cbic.201000201
Abstract
Glycosyltransferases (GTs) are a large family of enzymes that are essential in all domains of life for the biosynthesis of complex carbohydrates and glycoconjugates. GTs catalyse the transfer of a sugar from a glycosyl donor to a variety of acceptor molecules, for example, oligosaccharides, peptides, lipids or small molecules. Such glycosylation reactions are central to many fundamental biological processes, including cellular adhesion, cell signalling and bacterial- and plant-cell-wall biosynthesis. GTs are therefore of significant interest as molecular targets in chemical biology and drug discovery. In addition, GTs have found wide application as synthetic tools for the preparation of complex carbohydrates and glycoconjugates. In order to exploit the potential of GTs both as molecular targets and synthetic tools, robust and operationally simple bioassays are essential, especially as more and more protein sequences with putative GT activity but unknown biochemical function are being identified. In this minireview, we give a brief introduction to GT biochemistry and biology. We outline the relevance of GTs for medicinal chemistry and chemical biology, and describe selected examples for recently developed GT bioassays, with a particular emphasis on fluorescence-based formats.
Co-reporter:Thomas Pesnot Dr.;Monica M. Palcic Dr.
ChemBioChem 2010 Volume 11( Issue 10) pp:1392-1398
Publication Date(Web):
DOI:10.1002/cbic.201000013
Abstract
Glycosyltransferases (GTs) are a large class of carbohydrate-active enzymes that are involved, in both pro- and eukaryotic organisms, in numerous important biological processes, from cellular adhesion to carcinogenesis. GTs have enormous potential as molecular targets for chemical biology and drug discovery. For the full realisation of this potential, operationally simple and generally applicable GT bioassays, especially for inhibitor screening, are indispensable tools. In order to facilitate the development of GT high-throughput screening assays for the identification of GT inhibitors, we have developed novel, fluorescent derivatives of UDP-galactose (UDP-Gal) that are recognised as donor analogues by several different retaining galactosyltransferases (GalTs). We demonstrate for one of these derivatives that fluorescence emission is quenched upon specific binding to individual GalTs, and that this effect can be used as the read-out in ligand-displacement experiments. The novel fluorophore acts as an excellent sensor for several different enzymes and is suitable for the development of a new type of GalT bioassay, whose modular nature and operational simplicity will significantly facilitate inhibitor screening. Importantly, the structural differences between the natural donor UDP-Gal and the new fluorescent derivatives are minimal, and the general assay principle described herein may therefore also be applicable to other GalTs and/or proteins that use nucleotides or nucleotide conjugates as their cofactor.
Co-reporter:Jingqian Jiang, Varsha Kanabar, Beatriz Padilla, Francis Man, Simon C. Pitchford, Clive P. Page and Gerd K. Wagner
Chemical Communications 2016 - vol. 52(Issue 20) pp:NaN3958-3958
Publication Date(Web):2016/02/16
DOI:10.1039/C5CC09289B
We report 5-substituted uridine derivatives as novel, uncharged inhibitors of β-1,4-galactosyltransferase and chemical tools for cellular applications. The new inhibitors reduce P-selectin glycoprotein 1 (PSGL-1) expression in human monocytes. Our results also provide novel insights into a unique mode of glycosyltransferase inhibition.
Co-reporter:Karine Descroix and Gerd K. Wagner
Organic & Biomolecular Chemistry 2011 - vol. 9(Issue 6) pp:NaN1863-1863
Publication Date(Web):2011/01/26
DOI:10.1039/C0OB00630K
Structural analogues and mimics of the natural sugar-nucleotide UDP-galactose (UDP-Gal) are sought after as chemical tools for glycobiology and drug discovery. We have recently developed a novel class of galactosyltransferase (GalT) inhibitors derived from UDP-Gal, bearing an additional substituent at the 5-position of the uracil base. Herein we report the first C-glycosidic derivative of this new class of GalT inhibitors. We describe a practical convergent synthesis of the new UDP-C-Gal derivative, including a systematic study into the use of radical chemistry for the preparation of galactosyl ethylphosphonate, a key synthetic intermediate. The new inhibitor showed activity against a bacterial UDP-Gal 4′-epimerase at micromolar concentrations. This is the first example of a base-modified UDP-sugar as an inhibitor of a UDP-sugar-dependent enzyme which is not a glycosyltransferase, and these results may therefore have implications for the design of inhibitors of these enzymes in the future.
Co-reporter:Andrew Evitt, Lauren M. Tedaldi and Gerd K. Wagner
Chemical Communications 2012 - vol. 48(Issue 97) pp:NaN11858-11858
Publication Date(Web):2012/11/05
DOI:10.1039/C2CC36798J
A one-step synthesis of two 5-CF3 UDP-sugars is reported. These non-natural sugar-nucleotides are micromolar inhibitors of two different galactosyltransferases.
Co-reporter:Thomas Pesnot, Lauren M. Tedaldi, Pablo G. Jambrina, Edina Rosta and Gerd K. Wagner
Organic & Biomolecular Chemistry 2013 - vol. 11(Issue 37) pp:NaN6371-6371
Publication Date(Web):2013/08/14
DOI:10.1039/C3OB40485D
Derivatives of UMP (uridine monophosphate) with a fluorogenic substituent in position 5 represent a small but unique class of fluorophores, which has found important applications in chemical biology and biomolecular chemistry. In this study, we have synthesised a series of derivatives of the uracil nucleotides UMP, UDP and UTP with different aromatic and heteroaromatic substituents in position 5, in order to systematically investigate the influence of the 5-substituent on fluorescence emission. We have determined relevant photophysical parameters for all derivatives in this series, including quantum yields for the best fluorophores. The strongest fluorescence emission was observed with a 5-formylthien-2-yl substituent in position 5 of the uracil base, while the corresponding 3-formylthien-2-yl-substituted regioisomer was significantly less fluorescent. The 5-(5-formylthien-2-yl) uracil fluorophore was studied further in solvents of different polarity and proticity. In conjunction with results from a conformational analysis based on NMR data and computational experiments, these findings provide insights into the steric and electronic factors that govern fluorescence emission in this class of fluorophores. In particular, they highlight the interplay between fluorescence emission and conformation in this series. Finally, we carried out ligand-binding experiments with the 5-(5-formylthien-2-yl) uracil fluorophore and a UDP-sugar-dependent glycosyltransferase, demonstrating its utility for biological applications. The results from our photophysical and biological studies suggest, for the first time, a structural explanation for the fluorescence quenching effect that is observed upon binding of these fluorophores to a target protein.
Co-reporter:Giulia Pergolizzi, Julea N. Butt, Richard P. Bowater and Gerd K. Wagner
Chemical Communications 2011 - vol. 47(Issue 47) pp:NaN12657-12657
Publication Date(Web):2011/10/31
DOI:10.1039/C1CC15499K
A novel, fluorescent NAD derivative is processed as substrate by three different NAD-consuming enzymes. The new probe has been used to monitor enzymatic activity in a continuous format by changes in fluorescence and, in one case, to directly visualize alternative reaction pathways.
Co-reporter:Giulia Pergolizzi, Marco M. D. Cominetti, Julea N. Butt, Robert A. Field, Richard P. Bowater and Gerd K. Wagner
Organic & Biomolecular Chemistry 2015 - vol. 13(Issue 22) pp:NaN6398-6398
Publication Date(Web):2015/05/14
DOI:10.1039/C5OB00294J
We report the chemical synthesis and conformational analysis of a collection of 2-, 6- and 8-substituted derivatives of β-NAD+ and AMP, and their biochemical evaluation against NAD+-dependent DNA ligases from Escherichia coli and Mycobacterium tuberculosis. Bacterial DNA ligases are validated anti-microbial targets, and new strategies for their inhibition are therefore of considerable scientific and practical interest. Our study includes several pairs of β-NAD+ and AMP derivatives with the same substitution pattern at the adenine base. This has enabled the first direct comparison of co-substrate and inhibitor behaviour against bacterial DNA ligases. Our results suggest that an additional substituent in position 6 or 8 of the adenine base in β-NAD+ is detrimental for activity as either co-substrate or inhibitor. In contrast, substituents in position 2 are not only tolerated, but appear to give rise to a new mode of inhibition, which targets the conformational changes these DNA ligases undergo during catalysis. Using a molecular modelling approach, we highlight that these findings have important implications for our understanding of ligase mechanism and inhibition, and may provide a promising starting point for the rational design of a new class of inhibitors against NAD+-dependent DNA ligases.